Special Issue "New Insights in Multiple Myeloma"

Dear Colleagues,

It is my honor to serve as the Guest Editor of the Special Issue “New Insights in Multiple Myeloma” of the Journal of Clinical Medicine, and I would like to invite you to submit a relevant review and/or paper with new data from your research in the field. This Special Issue will serve as a great opportunity to highlight the main advances in this heterogeneous disease.

Multiple myeloma is perhaps the haematological neoplasia with more advances in the development of new therapies in the past two decades that have improved dramatically the prognosis. These new approaches include mainly immunomodulators, proteasome inhibitors, naked or conjugated monoclonal antibodies, bispecific T-cell engagers and CART therapies. Besides, high-dose alkilating agents, used as conditioning regimen for autologous transplants in younger myeloma patients, the use of chemotherapy has been practically eliminated from the therapy arsenal for this disease. With these new strategies a high percentage of patients achieve depth responses with long progression survival and some case could be considered with potential curability. New drugs and combinations are under clinical research for those patients who eventually relapse. Recent international treatment guidelines have been published and deserve continuous updates.

Other major advances for myeloma treatment include new tools to monitor minimal residual disease after therapy.  This involves all the disease steps with  new strategies for early detection of biological relapsed or progression with changes in the immune profile and the quantification of circulating  tumour plasma cells. The diagnosis and prognosis stratification of multiple myeloma is also being refined with new approaches as mass spectrometry, new image techniques and analysis of molecular genetic signature for personalized treatments. All these advances will be presented in this review by expert authors with a practical focus to improve the management of multiple myeloma patients.

I look forward to receiving your submissions.

Prof. Dr. Adrián Alegre
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• multiple myeloma
• stem cell transplantation
• immunotherapy
• precision medicine